SCHEMBL171307

SCHEMBL171307

CN(c1ccccc1)S(C)(=O)=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.54
CA12 O43570 2/20 0.53
CA9 Q16790 2/20 0.53
MCOLN3 Q8TDD5 1/20 0.47
NR3C2 P08235 1/20 0.47
HTT P42858 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
KDM4E B2RXH2 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
LMNA P02545 2/20 0.46
MAPK1 P28482 1/20 0.46
CA2 P00918 1/20 0.45
NPC1 O15118 1/20 0.44
TP53 P04637 1/20 0.44
RAB9A P51151 1/20 0.44
POLB P06746 1/20 0.44
HPGD P15428 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
BRD4 O60885 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27407425 0.93 ALDH1A1 (0.50) ALDH1A1CA12CA9MCOLN3NR3C2
SCHEMBL25137428 0.82 CA12 (0.55) CA12CA9MCOLN3NR3C2HTT
SCHEMBL10262610 0.81 CA12 (0.50) ALDH1A1CA12CA9MCOLN3NR3C2
SCHEMBL11551098 0.80 CA12 (0.53) CA12CA9MCOLN3NR3C2HTT
Lithium SCHEMBL31041149 0.80 CA12 (0.53) CA12CA9MCOLN3NR3C2HTT
SCHEMBL841253 0.78 CA12 (0.52) CA12CA9MCOLN3NR3C2HTT
SCHEMBL17227595 0.78 CA12 (0.52) CA12CA9MCOLN3NR3C2HTT
SCHEMBL5228279 0.78 CA12 (0.52) ALDH1A1CA12CA9MCOLN3NR3C2
SCHEMBL21034450 0.78 CA12 (0.52) ALDH1A1CA12CA9MCOLN3NR3C2
SCHEMBL3043906 0.78 CA12 (0.52) CA12CA9MCOLN3NR3C2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 344 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2014-01-02 US claimed
EP-2438063-A1 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis AG (CH) 2012-04-11 EP claimed
CN-101287805-B Marine antifouling coating compositions NOVUS INT INC 2011-11-02 CN claimed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US claimed
WO-2010139747-A1 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2010-12-09 WO claimed
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS NOVARTIS AG (CH) 2010-12-09 US claimed
CN-101287805-A Marine antifouling coating compositions NOVUS INT INC (US) 2008-10-15 CN claimed
EP-1910477-A1 USE OF A COMBINATION OF SUBSTANCES TO PREVENT BIOFOULING ORGANISMS I-Tech AB (SE) 2008-04-16 EP claimed
WO-2007015676-A1 USE OF A COMBINATION OF SUBSTANCES TO PREVENT BIOFOULING ORGANISMS I-TECH AB (SE) 2007-02-08 WO claimed
CN-1717176-A Fungicidal compositions ISAGRO SPA (IT) 2006-01-04 CN claimed
CN-1107449-C Liquid preservative for fruit and vegetable storage and preparation method thereof STATE AGRICULTURAL PRODUCT PRE (CN) 2003-05-07 CN claimed
CN-1334012-A Liquid preservative for fruit and vegetable storage and preparation method thereof STATE AGRICULTURAL PRODUCT PRE (CN) 2002-02-06 CN claimed
CN-1314083-A Sterilizing agent composition SHENYANG CHEMIAL RES INST (CN) 2001-09-26 CN claimed
CN-1029814-C bactericidal composition SHELL INT RESEARCH (NL) 1995-09-27 CN claimed
EP-0549668-A1 ANTI-HYPERTENSIVE TETRALINS THE WELLCOME FOUNDATION LIMITED (GB) 1993-07-07 EP claimed
WO-1992005143-A1 ANTI-HYPERTENSIVE TETRALINS THE WELLCOME FOUNDATION LIMITED (GB) 1992-04-02 WO claimed
CN-1030003-A bactericidal composition SHELL AGRAR GMBH & CO KG (DE) 1989-01-04 CN claimed
EP-3838903-B1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR INCYTE HOLDINGS CORP (US) 2023-11-22 EP disclosed
CN-87102872-A Stable pesticidal preparations 1987-10-28 CN disclosed
CN-86108526-A Bactericide 1987-07-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS PRKCA, ABL1, MYLK2 ALDH1A1 2472/4885CA12 4812/4885CA9 4676/4885
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 ALDH1A1 2405/4885CA12 4835/4885CA9 4728/4885
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 ALDH1A1 2405/4885CA12 4835/4885CA9 4728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.